中国基层医药
中國基層醫藥
중국기층의약
CHINESE JOURNAL OF PRIMARY MEDICINE AND PHARMACY
2014年
1期
49-51
,共3页
张连涛%梁贤栋%周文亮%任志强
張連濤%樑賢棟%週文亮%任誌彊
장련도%량현동%주문량%임지강
干扰素a-2b%阿德福韦酯%肝炎,乙型%肝炎,丙型
榦擾素a-2b%阿德福韋酯%肝炎,乙型%肝炎,丙型
간우소a-2b%아덕복위지%간염,을형%간염,병형
Interferon alfa-2b%Adefovir dipivoxil%Hepatitis B%Hepatitis C
目的 探讨干扰素联合阿德福韦酯治疗乙型肝炎和丙型肝炎重叠感染的临床疗效.方法 回顾性分析乙型肝炎和丙型肝炎重叠感染患者90例,根据治疗方法不同分为两组,对照组43例给予干扰素治疗,治疗组47例给予干扰素联合阿德福韦酯治疗,比较两组的临床疗效.结果 治疗48周后对照组HBV DNA及HCV RNA阴转率分别为32.6%、41.9%,治疗组分别为80.9%、72.3%,治疗组明显优于对照组,差异均有统计学意义(x2=6.43、5.28,均P＜0.05).结论 干扰素联合阿德福韦酯治疗乙型肝炎和丙型肝炎重叠感染患者具有良好效果,值得临床推广.
目的 探討榦擾素聯閤阿德福韋酯治療乙型肝炎和丙型肝炎重疊感染的臨床療效.方法 迴顧性分析乙型肝炎和丙型肝炎重疊感染患者90例,根據治療方法不同分為兩組,對照組43例給予榦擾素治療,治療組47例給予榦擾素聯閤阿德福韋酯治療,比較兩組的臨床療效.結果 治療48週後對照組HBV DNA及HCV RNA陰轉率分彆為32.6%、41.9%,治療組分彆為80.9%、72.3%,治療組明顯優于對照組,差異均有統計學意義(x2=6.43、5.28,均P＜0.05).結論 榦擾素聯閤阿德福韋酯治療乙型肝炎和丙型肝炎重疊感染患者具有良好效果,值得臨床推廣.
목적 탐토간우소연합아덕복위지치료을형간염화병형간염중첩감염적림상료효.방법 회고성분석을형간염화병형간염중첩감염환자90례,근거치료방법불동분위량조,대조조43례급여간우소치료,치료조47례급여간우소연합아덕복위지치료,비교량조적림상료효.결과 치료48주후대조조HBV DNA급HCV RNA음전솔분별위32.6%、41.9%,치료조분별위80.9%、72.3%,치료조명현우우대조조,차이균유통계학의의(x2=6.43、5.28,균P＜0.05).결론 간우소연합아덕복위지치료을형간염화병형간염중첩감염환자구유량호효과,치득림상추엄.
Objective To explore the clinical effect of IFN combined with adefovir dipivoxil in the treatment of patients with the hepatitis B and hepatitis C overlapping infection.Methods 90 cases of hepatitis B overlapping infection of hepatitis C were divided into control group(n =43) and treatment group(n =47).The control group was treated with IFN,the treatment group was treated with IFN and adefovir dipivoxil.Results The treatment group was better than the control group in the liver function,HBV DNA,HCV RNA.At the 24th weeks,the negative rates of HBV DNA and HCV RNA in the control group were 14 (32.6%) and 18 (41.9%),while there were were 38 (80.9%) and 34(72.3%) in the treatment group.There was significant differences between the two groups(x2 =6.43,5.28,all P ＜ 0.05).Conclusion The clinical efficacy of IFN combined with adefovir dipivoxil for the hepatitis B and hepatitis C overlapping infection patients was significant better than IFN,which is worthy of clinical application.
